Terumo OverviewLatest common stock for TRUMY: $39B.
Get informed when a big investor buys or sells
+ Follow
Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
As of the most recent data (June 2026), TRUMY shows a common stock of $39B. That compares with $39B in the prior-year period — up 0.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, TRUMY's common stock is now $39B (was $39B) — essentially flat versus a year earlier. Pairing that YoY change with peer averages gives a clearer picture of whether Terumo is outperforming or lagging.
Tracking TRUMY's common stock over time shows whether Terumo is scaling, shrinking, or reshaping that part of the business. The current reading is $39B That compares with $39B in the prior-year period — up 0.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this common stock page, Stockcircle has Terumo's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $39B) with ownership activity and broader fundamentals.
Terumo's common stock is $39B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
